Cartalax: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 3 de agosto de 2026

Cartalax is a short synthetic tripeptide (Ala-Glu-Asp; synonym AED) belonging to the family of short peptide bioregulators described by Khavinson's group. It is studied in research models as a tissue-targeted peptide associated with connective and cartilaginous tissue, with a proposed mechanism of gene-expression modulation. Independent evidence is limited and largely preclinical in nature. Product intended exclusively for research use.

Cartalax is a synthetic tripeptide with the sequence Alanyl-Glutamyl-Aspartate (Ala-Glu-Asp), also known by the synonym AED. It belongs to the class of "short peptide bioregulators" developed and studied primarily by the research group of V. Kh. Khavinson and collaborators in Saint Petersburg, a program that over several decades proposed a series of low-molecular-weight di-, tri- and tetrapeptides, each nominally associated with a target tissue or organ. Within this scheme, Cartalax has been conceptually linked to connective tissue, cartilage and the musculoskeletal system. It is important to note from the outset that the exact molecular formula and other formal physicochemical parameters do not appear in a standardized way in public chemical databases for the trade name "Cartalax" what is known directly is the amino acid sequence that gives it its name, a very short linear tripeptide, characteristic of this family of compounds.

From the structural standpoint, Cartalax is a very short-chain peptide composed of three residues: alanine, glutamic acid, and aspartic acid. Two of those three residues are acidic amino acids (glutamate and aspartate), which gives the molecule a markedly anionic character at physiological pH. This structural simplicity is the distinctive feature of the Khavinson bioregulators: they are minimal peptide fragments, in contrast to the larger polypeptides and proteins, and their brevity has been proposed as an advantage for cellular penetration and relative stability. Cartalax, a defined synthetic peptide, should not be confused with the older tissue-derived peptide extracts of the same program (the so-called "cytamins" or cartilage preparations); Cartalax corresponds to the generation of short peptides of known sequence chemically synthesized.

The proposed mechanism of action for short peptide bioregulators, and by extension for Cartalax, falls within the hypothesis of epigenetic regulation by peptides. According to the model proposed by the Khavinson group, these low-molecular-weight peptides would be capable of crossing the cell and nuclear membranes and interacting directly with specific regions of DNA or chromatin, thereby modulating the expression of certain genes and, consequently, the synthesis of tissue proteins. For peptides of this family, in vitro and in silico models have proposed a possible affinity for DNA sequences and an influence on transcriptional activity, as well as effects on cell proliferation and differentiation in culture. In the specific case of a peptide directed at connective and cartilaginous tissue, the working hypotheses have centered on modulating the activity of cells such as fibroblasts and chondrocytes and on extracellular matrix homeostasis. It should be emphasized that these mechanisms are largely working hypotheses derived from a limited body of literature and do not constitute a molecular mechanism fully validated by broad independent replication.

As for documented research applications, Cartalax has been explored in the general context of studies on tissue-specific peptides and the aging of connective tissue. The lines of inquiry associated with this family include models of cellular senescence, proliferation assays in cultures of fibroblasts and chondrocytes, and studies on extracellular matrix markers. However, most of the available evidence for Cartalax specifically is scarce, comes predominantly from the same research group that introduced the compound, and lies in the preclinical realm (animal models, cell cultures, and computational analyses), without large-scale independent clinical trials that confirm the proposed effects. This clearly distinguishes it from classes of peptides with consolidated pharmaceutical development.

The level of evidence must therefore be honestly described as limited. For Cartalax there is no robust body of randomized clinical trials replicated by multiple independent groups, nor an approval as a drug by leading international regulatory agencies that would support therapeutic claims. Much of what has been published on short peptide bioregulators, including this tripeptide, comes from a single research lineage, and the broader scientific community has noted the need for external validation. Consequently, any characterization of Cartalax must be presented as exploratory research material: a synthetic tripeptide of known sequence (Ala-Glu-Asp), from the family of Khavinson bioregulators, with a proposed but not fully established epigenetic mechanism, and with applications that remain in the preclinical domain.

For the purposes of a research laboratory, Cartalax is handled like the other short lyophilized peptides: it is supplied as a lyophilized powder for reconstitution and handling under controlled conditions. Researchers working with this compound should rely on the available primary literature, interpret results with caution given the limited nature of the evidence, and design their protocols with adequate controls that allow real effects to be distinguished from experimental artifacts.